The pharmacokinetic properties of Daclatasvir were evaluated in healthy adult subjects and in subjects with chronic HCV. Administration of Daclatasvir tablets in HCV-infected subjects resulted in approximately dose-proportional increases in Cmax, AUC, and Cmin up to 60 mg once daily. Steady state is anticipated after approximately 4 days of once-daily Daclatasvir administration. Exposure of Daclatasvir was similar between healthy and HCV-infected subjects

Available As: 60 Mg